

February 13, 2008

To all stakeholders

Company name: SFCG Co., Ltd.  
Representative Officer: Kenshin Oshima  
Director and President  
(Security code: 8597, 1st section of Tokyo Stock Exchange)  
Enquiry: Toshihiro Takeshita  
Director and General Manager  
Accounting Division  
TEL +813-3270-4177 (03-3270-4177)

**Notice of Sale of BIOFERMIN PHARMACEUTICAL Stock**

TZCS, INC. (Head office: Tokyo, President: Naoki Yoshida), which is a subsidiary of SFCG Co., Ltd., will submit its shares of BIOFERMIN PHARMACEUTICAL CO., LTD. for sale under the terms of the tender offer conducted by Taisho Pharmaceutical Co., Ltd. (Tokyo Stock Exchange 1<sup>st</sup> section, 4535), one of Japan's major pharmaceutical companies. BIOFERMIN PHARMACEUTICAL (Osaka Securities Exchange 1<sup>st</sup> section, 4517), an equity-method affiliate of SFCG, is a manufacturer of a variety of pharmaceuticals. The board of directors of TZCS approved a resolution on February 12, 2008 to sell all BIOFERMIN PHARMACEUTICAL shares held by TZCS (4,884,100 shares, which is about 40.2% of all shares issued) to Taisho Pharmaceutical in accordance with the tender offer.

SFCG will announce the effect of this sale on its operating results once the monetary amounts have been determined.